申请人:Ono Naoya
公开号:US20100234594A1
公开(公告)日:2010-09-16
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof:
(wherein Y
1
represents a nitrogen atom or a group represented by CR
A
, Y
2
represents a nitrogen atom or a group represented by CR
B
, Y
3
represents a nitrogen atom or a group represented by CR
C
, R
A
, R
B
and R
C
, which may be the same or different, each represent a hydrogen atom, etc. (excluding the case where Y
1
is CR
A
, Y
2
is CR
B
and Y
3
is CR
C
), X represents an oxygen atom, etc., R
1
represents a C
1
-C
6
alkyl group, etc., R
2
represents a C
1
-C
6
alkyl group, etc., R
3
represents an optionally substituted phenyl group, etc., R
4
represents a hydrogen atom, etc., and R
5
represents an optionally substituted phenyl group, etc.) has an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P
1
), and is useful as a therapeutic agent for autoimmune diseases, rheumatoid arthritis, asthma, atopic dermatitis, rejection after organ transplantation, cancer, retinopathy, psoriasis, osteoarthritis, or age-related macular degeneration, etc.